When you microdose a psychedelic, you take roughly one-tenth of a full dose, an amount too small to cause hallucinations or a “trip.” The goal is subtle shifts in mood, focus, or creativity that fold into a normal day. People who microdose typically report feeling slightly sharper, more emotionally open, and more energized. But the science on whether those effects are real or driven by expectation is more complicated than most people realize.
What Counts as a Microdose
For psilocybin mushrooms, a microdose falls between 0.1 and 0.5 grams of dried material. For LSD, it ranges from about 5 to 20 micrograms, compared to the 100 to 200 micrograms in a typical full dose. At the low end (0.1 grams of mushrooms, or roughly 5 micrograms of LSD), most people feel almost nothing consciously. At the higher end, some people notice mild perceptual shifts: colors may seem slightly richer, or music may feel more absorbing. The line between “sub-perceptual” and “threshold” is blurry and varies from person to person.
How It Feels and How Long It Lasts
A microdose of psilocybin or LSD typically takes 30 to 60 minutes to kick in. Subjective effects tend to peak around two to three hours after ingestion, then gradually taper off. The entire window lasts roughly six to seven hours for LSD and slightly shorter for psilocybin. During that time, people commonly describe a subtle lift in mood, slightly sharper attention, or a sense of being more present. Some describe it as the feeling of having had a particularly good night’s sleep or an excellent cup of coffee, without the jitteriness.
In a large survey that coded over 800 self-reported benefits, the most frequently mentioned effects were improved mood (reported by about 27% of respondents), improved focus (15%), enhanced creativity (9%), and increased energy (8%). Those numbers come from open-ended descriptions, not forced-choice questionnaires, so they reflect what people spontaneously noticed most.
What’s Happening in Your Brain
Psychedelics like LSD and psilocybin are best known for activating a specific serotonin receptor (5-HT2A), which is what produces hallucinations at full doses. But a 2023 study in Nature Neuroscience revealed something unexpected: these compounds also bind directly to a growth-factor receptor called TrkB, which helps brain cells form new connections. LSD binds to this receptor with roughly 1,000 times more affinity than conventional antidepressants like fluoxetine.
This matters because TrkB is the main receptor for BDNF, a protein that acts like fertilizer for neurons, promoting the growth of new branches and connections between brain cells. LSD essentially locks this receptor into a shape that makes it more responsive to BDNF, boosting the brain’s natural plasticity signaling. Intriguingly, the researchers found that the antidepressant-like effects in mice depended on this TrkB binding, not on serotonin receptor activation. That suggests psychedelics may promote brain flexibility through a pathway entirely separate from the one that causes hallucinations.
The Placebo Problem
Here’s where things get uncomfortable for microdosing enthusiasts. When researchers run rigorous, double-blind, placebo-controlled trials where neither participants nor experimenters know who got the real dose, the benefits largely disappear. Two recent randomized trials testing microdosed psilocybin truffles found null effects on attention, mood, cognitive control, and self-reported well-being compared to placebo. The researchers concluded that microdosing psilocybin did not reliably enhance cognitive or emotional functioning beyond what a sugar pill could do.
This doesn’t necessarily mean microdosing does nothing. It means that a large portion of the positive experiences people report may come from expectation, ritual, and the belief that they’ve taken something powerful. Psychedelics carry enormous cultural meaning, and simply deciding to start a microdosing practice involves intentional changes to routine, mindset, and self-monitoring that can themselves shift how you feel. Separating the drug effect from the mindset effect is one of the hardest problems in psychedelic research.
Creativity and Cognitive Flexibility
One area where effects do show up, at least at slightly higher doses, is cognitive flexibility: the ability to shift between different ideas or problem-solving strategies. In studies of people with depression, psilocybin therapy reduced rigid thinking patterns, with improvements lasting at least four weeks after treatment. In healthy volunteers, psilocybin actually impaired creative thinking during the acute experience (the hours right after taking it) but improved it seven days later, with people generating more novel ideas for everyday objects compared to placebo.
Self-reported cognitive flexibility also showed small but statistically significant improvements that persisted for two to three months after psilocybin sessions. The effect sizes were modest, roughly in the range of a 0.2 standard deviation improvement. That’s not a dramatic shift, but it’s consistent and it lasted. Whether these findings from therapeutic-dose studies translate to the much smaller amounts used in microdosing remains unclear.
Common Schedules and Protocols
Most people who microdose follow a schedule rather than taking a dose every day. The most popular approach, sometimes called the Fadiman protocol, involves taking a microdose every fourth day for several weeks, then taking a break before starting again. The logic is that tolerance builds quickly with psychedelics, so spacing out doses preserves their effect and prevents habituation.
Another approach, associated with mycologist Paul Stamets, combines a psilocybin microdose with lion’s mane mushroom and niacin (vitamin B3). The idea is that lion’s mane supports nerve growth on its own, while niacin helps distribute the compounds more broadly through the body. This “stacking” protocol is popular in online communities, though it hasn’t been tested in controlled trials.
Many experienced microdosers eventually abandon fixed schedules entirely and dose based on how they feel, taking it only on days when they want a cognitive or emotional boost. This intuitive approach is common but makes it harder to distinguish genuine drug effects from the placebo response.
Risks and Side Effects
Microdosing is generally considered low-risk compared to full psychedelic experiences, but it’s not risk-free. In the same large survey that cataloged benefits, 18% of respondents reported physiological discomfort (headaches, nausea, or body tension) and about 7% experienced increased anxiety. Some people find that even small doses amplify whatever emotional state they’re already in, so taking a microdose on a stressful day can make the stress feel more intense rather than less.
Drug interactions are a more serious concern. Lithium, a common mood stabilizer, has been linked to seizures when combined with LSD or psilocybin in multiple case reports. Combining psychedelics with SSRIs (common antidepressants like fluoxetine or sertraline) can blunt the psychedelic effect, but in some cases has caused dangerous blood pressure spikes or symptoms resembling serotonin syndrome: agitation, rapid heartbeat, and overheating. If you take any psychiatric medication, combining it with a microdose is not straightforward and can be genuinely dangerous.
There’s also a longer-term concern that hasn’t been resolved. Psychedelics activate a serotonin receptor (5-HT2B) that, when stimulated chronically, is associated with heart valve thickening. This is the same mechanism that caused drugs like fenfluramine to be pulled from the market. A 2023 analysis found that LSD, psilocybin, and related compounds bind to this receptor with potency equal to or greater than their binding at the receptor responsible for psychedelic effects. The safety margins from typical microdoses were larger than those of known heart-damaging drugs, but the researchers couldn’t rule out risk with long-term use. No clinical study has directly measured whether regular microdosing over months or years affects heart valves.
Legal Status
Psilocybin and LSD remain Schedule I controlled substances under U.S. federal law. Oregon was the first state to create a regulated framework for supervised psilocybin therapy, and Colorado followed with its own program. Several other states have active legislative efforts: Arizona signed a bill in 2025 related to psychedelic access, and Massachusetts has multiple bills in its legislature proposing licensed therapeutic psilocybin centers. But personal, unsupervised microdosing remains illegal in most of the country. Some jurisdictions have “decriminalized” possession, meaning law enforcement treats it as the lowest priority, but decriminalization is not the same as legality.